Invezz
02 Jul 2026, 19:51 UTC · 1h ago
Moderna stock jumps as pipeline progress and flu shot data lift sentiment
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Invezz
02 Jul 2026, 19:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
An FDA advisory panel unanimously supported Moderna's mRNA-1010/mFLUSIVA influenza vaccine for adults aged 50 and older. — Unanimous panel support is a high-probability precursor to FDA approval, potentially diversifying the company's revenue beyond COVID-19.
+0.80Moderna shares rose 9.2% on Thursday following positive pipeline updates and influenza vaccine data. — Strong immediate price action confirms market confidence in the company's shift toward a multi-product platform.
+0.40The PDUFA decision date for the influenza vaccine is set for August 5, 2026. — Provides a concrete timeline for the next major binary regulatory event, though it is far in the future.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Stock jumped significantly due to positive FDA advisory panel support for its influenza vaccine and encouraging pipeline progress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
5h ago
